Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2020
Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy.
Open access · greenAbstract readClinical Trial, Phase IIMulticenter Study
In one paragraph
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- Comparing Biomarkers for Predicting Pathological Responses to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER).The oncologist · 2025Trial
- Phase II Trial Assessing the Repeatability and Tumor Uptake of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Trial
- Vitamin B5 supports anti-PD1 response in HER2-positive gastric cancer and enhances interaction between naïve B cells and T cells.Nature communications · 2026Article
- Sequential involvement of hypoxia and anti-PD-1 treatment in shaping tumor-regional CD39Journal for immunotherapy of cancer · 2026Article
- Tumor-Intrinsic PD-1 Regulatory Network Drives Lapatinib Resistance in HER2⁺ Breast Cancer: An Integrative Bioinformatics Analysis.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- MicroRNA-mediated modulation of cancer-associated fibroblasts in HER2-positive breast tumor microenvironment: a comprehensive review.Discover oncology · 2026Review
- The Correlation Between CD8+ Tumor-Infiltrating Lymphocytes and the Efficacy of Neoadjuvant Therapy in Breast Cancer.Breast cancer (Dove Medical Press) · 2026Article
- B-cells in breast cancer: current insights and challenges.Frontiers in oncology · 2026Review
- The landscape of dynamic tumor immunophenotyping on neoadjuvant chemotherapy combined with trastuzumab for the treatment of HER2-positive breast cancer.Molecular cancer · 2025Article
- Advances in the intrinsic signaling pathway interactions and clinical translation of HR+/HER2+ breast cancer.Breast cancer (Tokyo, Japan) · 2025Review
- Roles of Tumor-Infiltrating Lymphocytes and Antitumor Immune Responses as Predictive and Prognostic Markers in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy.International journal of molecular sciences · 2025Review
- Immuno-Oncology at the Crossroads: Confronting Challenges in the Quest for Effective Cancer Therapies.International journal of molecular sciences · 2025Review
- Correlation study of tumor-infiltrating lymphocytes (TILs) and subtypes analysis before and after neoadjuvant chemotherapy in triple-negative breast cancer.Gland surgery · 2025Article
- Spatial proximity of CD8NPJ breast cancer · 2025Article
- Distribution characteristics and prognostic value of TIM-1 in patients with lung adenocarcinoma.Frontiers in immunology · 2025Article
- Association of the inflammatory microenvironment of obesity with pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy.Frontiers in endocrinology · 2025Article
- HER2-Positive Breast Cancer Treatment and Resistance.Advances in experimental medicine and biology · 2025Review
- The interplay between the immune response and neoadjuvant therapy in breast cancer.Frontiers in oncology · 2025Review
- The association of PD-L1 expression and CD8-positive T cell infiltration rate with the pathological complete response after neoadjuvant treatment in HER2-positive breast cancer.Breast cancer research and treatment · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 6 institutions in 3 countries.
Carmine De AngelisLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Chandandeep NagiLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Cliff C HoytAkoya Biosciences, Hopkinton, Massachusetts.
Linying LiuAkoya Biosciences, Hopkinton, Massachusetts.
Kristin RomanAkoya Biosciences, Hopkinton, Massachusetts.
Chichung WangAkoya Biosciences, Hopkinton, Massachusetts.ORCID 0000-0003-1957-7160
Yi ZhengAkoya Biosciences, Hopkinton, Massachusetts.
Jamunarani VeeraraghavanLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Vidyalakshmi SethunathLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Paolo NuciforoBreast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.ORCID 0000-0003-1380-0990
Tao WangLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0003-1957-7160
Anna TsimelzonLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Sufeng MaoLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Susan G HilsenbeckLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-7962-673X
Meghana V TrivediLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-0585-5580
Maria Letizia CataldoLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Anne PavlickLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Antonio C WolffThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.ORCID 0000-0003-3734-1063
Britta WeigeltDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Jorge S Reis-FilhoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Aleix PratDepartment of Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain.
Carolina GutierrezLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Charles Kent OsborneLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Mothaffar F RimawiLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Rachel SchiffLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas. rschiff@bcm.edu.ORCID 0000-0003-1696-5213
Baylor College of Medicine · USAkoya Biosciences (United States) · USMemorial Sloan Kettering Cancer Center · USBreast Cancer Research Foundation · USSidney Kimmel Comprehensive Cancer Center · USVall d'Hebron Institut de Recerca · ES
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Michael M Ittmann · 2007 to 2026
$73.9MTUMOR SUPPRESSOR GENES IN BREAST CANCER DEVELOPMENTP50CA058183 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI GUTIERREZ, CAROLLINA · 1992 to 2012
$30.9MTranslational Research in Breast Cancer (SPORE)P50CA186784 · NCI · BAYLOR COLLEGE OF MEDICINE · PI MATTHEW J ELLIS · 2014 to 2026
$24.5MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA125123NCI NIH HHS P50 CA058183NCI NIH HHS P50 CA186784
Abstract
purposeTumor-infiltrating lymphocytes (TIL) are associated with benefit to trastuzumab and chemotherapy in patients with early-stage HER2
resultsThe pathologic complete response (pCR) rate was numerically higher in patients with LPBC compared with patients with non-LPBC (50% vs. 19%,
conclusionsLPBC was marginally associated with higher pCR rate than non-LPBC in patients with lapatinib plus trastuzumab treated HER2
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up StudiesHumansLapatinibLymphocytesLymphocytes, Tumor-InfiltratingMiddle AgedNeoadjuvant TherapyPrognosisTrastuzumabERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesLapatinibTrastuzumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.